Healthcare / Drug Manufacturers - Specialty & GenericKSE
$38550.00
-500.00 (-1.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-38.7B · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$371.8B
P/E
N/A
•EV/EBITDA
59.1x
↑ROE
-4.4%
↓Gross Margin
44.6%
↓Debt/Equity
0.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.4%
FCF CAGR
—
FCF margin
-1.0%
FCF / Net income
0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $808.78B · net income $-28.59B · FCF $-7.85B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $808.78B | $808.78B | $697.87B | $663.98B | $635.39B |
| Net Income | $-28.59B | $-28.59B | $-1.22B | $11.12B | $13.55B |
| EBITDA | $12.59B | $12.59B | $28.99B | $45.07B | $46.49B |
| EPS | -2970.48 | -2970.48 | -134.45 | 1194.21 | 1334.65 |
| Gross Margin | 44.6% | 44.6% | 48.7% | 49.4% | 49.6% |
| Operating Margin | 0.1% | 0.1% | -3.6% | 1.7% | 2.7% |
| Net Margin | -3.5% | -3.5% | -0.2% | 1.7% | 2.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.84 | 0.84 | 0.74 | 0.62 | 0.46 |
| Current Ratio | 1.50 | 1.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.85B | $-7.85B | $-43.88B | $-38.65B | $-35.97B |
| Returns | |||||
| ROE | -4.4% | -4.4% | -0.2% | 1.7% | 2.0% |
| Valuation | |||||
| P/E | — | — | — | 52.07 | 41.22 |
| EV/EBITDA | 59.13 | 59.13 | 28.24 | 19.05 | 13.04 |
| P/B | 0.58 | 0.58 | 0.76 | 1.01 | 0.83 |
| Growth & Yield | |||||
| Revenue Growth | 15.9% | 15.9% | 5.1% | 4.5% | — |
| EPS Growth | -2109.3% | -2109.3% | -111.3% | -10.5% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-134.45 → -2970.48
Residual
-12.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.